These results suggested that gene therapy targeting Ezrin in skeletal muscle could be a potential candidate treatment strategy for CMT4F-associated muscle atrophy characterized by mutation or loss of L-periaxin. The gene discussed is EZR; the disease is Charcot-Marie-Tooth disease type 4F.